Abstract: The extent of lymph node (LN) metastasis is a major determinant for the staging and the prognosis of most human malignancies and often guides therapeutic decisions. Although the clinical significance of LN involvement is well clocumentecl, little has been known about the molecular mechanisms that promote tmnor spread via lymphatic vessels to sentinel and £listal LN and beyond. However, recent discoveries have identified novel lymphatic-specific markers, and the newly discovered lymphangiogenesis factors vascular endothelial growth factor-C (VEGF-C) and VEGF-D were found to promote tumor-associated lymphatic vessel growth in mouse tumor models, leading to enhanced tumor spread to sentinel LN. Our t•ecent findings indicate that VEGF -A also acts a s a potent tumor lymphangiogenesis factor that pt·omotes lymphatic tmnor spread. VEGF-A overexpressing primary tumors induced sentinel LN lyntphangiogenesis even before metastasizing and maintained theit· lymphangiogenic activity after m e tastasis to draining LN . Our recent studies showed that primary human melanomas that later metastasized wet·e chm·acterized hy increased lymphangiogenesis and that the degree of tumor lymphangiogenesis can serve as a novel predictor of LN metastasis and overall patient survival, independently of tumot· thickness. Tumor lymphangiogenesis also signifieantly predicted the presence of sentinel LN metastases at the time of surgical excision of the primary melanoma. Together, these findings suggest that tmnor lymphangiogenesis actively contributes to cancer dissemination, that blockade of lymphatic vessel growth might inhibit tumor metastasis to LN, and that the extent of tumor-associated lymphangiogenesis could serve as a novel, prognostic parameter for the metastatic risk of human cancers. J, Leukoc. Biol. 80: 691-696; 2006. 
INTRODUCTION
Higher eukaryotes possess two vascular systems: the blood and the lymphatic system. The blood vasc ulature contains a basal membrane and smooth muscle cells and per. icytes surrounding the blood vasc ular endothelial cells. Blood flow is organized in 0741-5400/06/0080-691 © Society for Leukocy te Biology a circular manner, driven by th e heart, and the blood vasculature is the main conduit for transporting oxygen, carbon dioxide. nutrients, and metabolic products, cells of th e immune system, hormones, and other fac tors. In contrast, the lymphatic system consists of the lymphoid organs such as thymus, bune marrow, lymph nodes (LN), tonsil s, Peyer's patches, spleen, and the lymphatic vessels, which are present in almost all tissues but are absent from avasc ular structures such as the epidermis, hair, nails, cartilage, and cornea and from some vascularized orga ns such as brain and reti na. Lymphatic capil laries are blind-ending in the periphery and consist of a single layer of lymphatic endothelial cells (LECs), which are not surrounded by pericytes, smooth musele cells, or a regular basement membrane [l] . LECs are anchored to the extracell ular matrix by elastic anchoring filaments, which cause the lymphatic vessels to dilate rather than to collapse when hydrostatic pressure in the tissue increases.
The major function of lymphatic vessels is to coll eet and to transport protei n-rich interstitial fluid via LN, larger collecting lymphati c vessels, and the thoracic duct to the subclavian vein and thereby. bac k to th e blood vascular circulati on. Lymphatic flow is activated mainly by contraction of smooth muscle cells covering larger collecting lymphatic vessels, by arterial pulsations, and by the action of neighboring skeletal mu scles. In larger lymphatic vessels, valves prevent backflow. In addi tion to its role in tissue press ure homeostasis, the lymphatic system contributes to the immune surveillance of the body by attracting and transporting activated immune cell s such as dend rit ic cells (DC) from the skin to the regional LN [2] . In addition. lacteal ly mphatic: vessels within the intestinal villi are involved in uptak e of di etary fat and of th e fat-soluble vitamins i\ . D, E, and K. The lymphatic system also plays a major role in ti ssue repair [3. 4] , chroni c inflammation [5] , lymphedema [6] , and tumor metastasis [1, 7] .
Several pathways may contribute to the dissemination of primary malignant cancer cells: local invasion into the surrounding tissue, systemic me tastasis via tumor-associated blood vessels to distant organs, and lympha tic metastasis via tumorassociated lymphatic vessels to draining (sentinel) LN, distal LN, and from there to distal organs (Fig. 1) . The extent of LN me tastasis is a maj or determinant for the s taging and the prognosis of most human malignancies and often guides therapeutic decisions. Although the clinical significance of LN involvement is well documented, little is known about the molecular mechanisms th at promote tumor spread via lymphatic vessels to sentinel and distal LN and beyond. A traditional view has assigned a rather passive role to lymphatic vessels during the process of LN metastasis, assuming tha t tumor cells are passively taken up by lymphatic vessels along wi th the protein-ric h interstiti al fluid [8] . It has also been proposed that entry of cancer cells into the lymphatic vascula ture might be facilitated by the higher permeability of lymphatic vessels, as compared with blood vessels, and by the absence of a regular basement membrane barrier [9] .
Hesearch into the role of the lymphatic system in cancer me tastasis has been hampered by the lack of specific markers that d is tinguish lymphatic vessels from blood vessels and by the lack of identified lymphatic-specific growih factors . Ho we ver, recent discoveries have identified novel lymphatic-specific markers, includi ng podoplanin [10] , lymphatic vasc ular endothelial cell h yaluronan receptor-! (LYVE-1) [11], and Proxl, a homeobox transcription factor th at induces lymphatic, lineage-specific differentiation and that is essential for the embryonic development of th e lymphatic system from the blood vascular system [12, 13] . Furthermore, vascular endothelial growth factor-C (VEGF-C) and VE GF-D have been discovered as novel members of the VEGF fam ily of a ngiogenic factors, which specifically activate VEGF receptor-3 (VEGFR-3) expressed on lymphatic endothelium [14, 15] . Indeed, transgenic overexpress io n of VEGF-C in the skin promotes cutaneous lymphangiogenesis [16] , whereas the targe ted disruption of VEGF-C in mice leads to a failure of early lymphatic endo- thelia! cells to mi grate away from cardinal ve ins and to form lympha ti c vessels [ 17] .
Based on these findings, we and others [18] [19] [20] have recently discovered that VEGF-C (and also th e related fac tor VEGF-D) promotes tumor-associated lymphatic vessel gro wth (tu mor lymphangiogenesis) in xenotransplant and transgenic mo use tumor models and that this promotes sentinel LN metastasis . We fou nd that in an orthotopic breast cancer model in immunodeficient mice, overexpression of VEGF-C by tumor cells induced growth and enlargement of tumor-associated lymphatic vessels within and surrounding these tumors [19] . These tumor-induced lymphatic vessels we re actively proliferating and occasionally contained tumor cells. It is im portant that VEGF-C expression and increased tumor lymphangiogenesis were associated with enhanced tumor metastasis L o sent inel LN. Together, these fi nd ings s ugges t that tumor lymphangiogenesis actively contributes to cancer dissemination , that blockade of lymphatic vessel growth mi ght inhibit tumor metastasis to LN, and that the extent of tumor-associated lymphangiogenesis could serve as a novel prognostic paramete r for the metastatic risk of human cancers .
The biological relevance of intratumoral lymphatic vessels has remained unclear. Proliferati ng intratumoral lymphatics have been observed in tu mor xenotransplan ts and in sl owly growing, chemically induced , orthotopic squamous cell carcinom as (SCC) in mice, as well as in primary human malignant melanomas of the s kin, which metastasized to LN [19, [21] [22] [23] .
Conversely, intratumoral lymphatic vessels withi n experimental tumors in mice mi ght not be fun ctional with regard to fluid transport [24] , and a recent study has observed efficient experimental prostate cancer metastasis to LN in the absence of intratumoral lymphatics [25] . Although the functionality of lymphatics wi th rega rd to fl uid transport does not necessaril y reflect their ability to gu ide tumor cells toward th e draini ng LN, e.g., via secre tion of chemokines such as CC chemokine ligand 21, whi ch has been shown to attract DC and CC chemokin e receptor ?-expressing tumor cells toward LN [2, 26] , th e majority of studi es indicates that peritumoral lymphatic vessels [21, 24. 27 ]. and they have been shown to actively proliferate [28] . It has been our own experience that quantitation of lymphatic " ho t spots" in the peri tumoral area of melanomas of the skin more accurately pred icted LN metastas is than the evaluation of intratumoral lymphatics, and diverging results observed in diflerent studies might be caused by different analysis methods used for the quan titation of tumor lymphangiogenesis . These include the analysis of peri-versus intratumoral vessels. of hot spots versus total tumor area, and of specilic lymphatic sta ins (LY\TE-1, Podoplanin, Proxl) versus indirec t detection of lymphatic vessels (e.g., CD3l-pos itive/pathologische anatomic Leiden-endothelium (PAL-E)-negative vessels).
In human cancers, a strong correlation between the expresiun levels of the lyrnphangiogenic fa ctor VEGF-C (and less often, VEGF-D) and LN metastasis was found in more than 30 retrospective studies (for revi ew. see refs. [9, 29. 30 ]). Our own recent studies in human c utaneous. malignant melanomas demonstrated the presence of tumor-associated lyrnphangiogene is [22] . They also showed that metastatic melanomas were characterized by increased lymphangiogenesis as compared with nonmetastatic tumors and that the degree of tumor lymphangiogenesis can serve as a novel pred ictor of LN 1netastasis and overall patient survivaL independently of tu mor th ic kness . Tu mor lymphangiogenesis and levels of tu mor-expressed VEGF-C also significantly predicted th e presence of sentinel LN metastases at the time of surgical excision of the primary melanoma [.31 ]. Further studies involving huger numbers of eases are needed to confirm these findings. It is tempting to S!Jeeulate that lymphangiogenic factors, in addition to inereasing th e mass of tumor-associated lymphatic vessels. mi ght activatf' the lymphati c endothelium to expre--s increased amoun t:; of chemokin es or ad hesion molecules and reeeptors. whi ch are involved in tumor cell -LEC interaction:;. thereby acti vdy contributing to cancer di ssemination.
Likely, leukocytes also play an impo1iant rol e in promoting tumor-associated lymphatic vessel growth and activation. Activated macrophages express VEGFH.-3, and the lymphangiogeuic fa<' tor VEGF-C has been shown to enhance macrophage chemot axis [32. 33] . [n tum.
•lctiv•lled macrophages sec rete lymphangiogenic factori" including VEGF-C [33]. Recently, VEGF-A secreted by follicular B cells has been implicated in the mediation of LN lymphangiogenesis [. 34 ]. The relative contribution of leukocyte-deri \·ed lymphangioge nic factors remai ns unclear at present. [t has been proposed th at bone marrow-derived progenitor ce ll s and maerophages might be physil'ally in corporat ed into newly formed lymphatic ve sels [35] [36] [37] has not been observed in tumor-associat ed lymphangioge nesis [38] .
VEGF-A PROMOTES TUMOR LYMP HANGIOGENESIS AND LN METASTASIS
VECF-A ha,; heen seen traditionally as a blood vessel-s pecific gro wth factor. However, its major signaling receptor, VEGFH-2 . is also expressed by LECs in vi tro and in vivo [4, 39] , and treatment of cultured LECs with VEGF-A potently promotes LEC proliferation [40. 4 1] . Moreover, adenoviral delivery of murine VEGF-A164 into mouse ears resulted in the new formation of enla rged and tmiuous lymphatic vesseb. which persisted over several months (42] , and transgen ic delivery of VEGF-A to the skin promoted lymphangiogenesis associated with tissue repair [4] and with chronic inilammatio n [.5 ]. As most human and mo use cancers strongly expre:s~ VEGF-A [43] and as an association between VEGF-A production and LN metastasis has been found in several cancer types including gastric cancer 144 ]. we hypot hesized that VECF-A might also promote tumor lymphangiogenesis and LN metastasis.
To directly investigate the biologica l role of VEGF-A during tumor progression, we recently created transge nie mi ce that overexpress VEGF -A and green fluore. cent protein s pec ifically in the skin and subjected th em to a standard, chemi cally induced skin carcinogenesis regimen. W'e found that VE GF-A not only strongly promoted multiste p sk in carc inogenes is but also induced aeti ve proliferation of VEGFR-2 express ing tumor-associated lymphatic vessels as well as tumor metastas is to the sentinel and eli. tant LN [28] . The lymphangiogeni c activity of VEGF-A-express ing tumor cells was maintained even after their metastasis to draining sentinel LN. The nw ' t surpri sing finding of this study was that even before metastasizing, VEGF-A-overexpressi ng primary tumors induced sentinel LN lymphangiogenesis lFig. 2 ). This suggests th at primary tumors might begin preparing th eir future metas tatic site by producing lyrnphangiogenic factors th at mediate th e ir efficient transport to sentinel LN . The newly identif-ied mechani sm of indueing LN lymphangioge nes is likely contribute:; to tumor metastas is and migh t represent a new th erapeutic target lor advanced cancer and/or for the pre ve ntion of metastasis.
The relative contribu tion of direct (via activation of VEGFH.-2 Oil l ECs) versus indirect effects toward the lymphangiogeni c ac tivity of VEGF-A remains to be explored. VEGF-A has been shown to indu ce VEGF-C ex press ion in cultured blood vascular endothelial cells, and VEGF-A-produeing transge ni c tumors indeed showed higher VE GF-C protein l.evels than wild -type tumors [28] . In a recent s tudy. VEGF-A-expressing tmnors also contained higher numbe r::; of macrophages [27] , which migh t l~<w e contribu tecllymph ang iogenic mediators . However, lymphatic vessels associated with VEGF-A-expressing tumors strongly expressed VFGFH-2, and VE GF-A-induced LEC migration in <'ulture involves at:tivatiun of spec if-ic integrin ligands, whi ch are independent of VEGFR-:3 activation [4] . As VEGF-A regulates the expression of adhes ion moleeules in blood vesse ls 14.5. 46] . this mig ht also be the case in lymphatic ve.-:;els. Further studies are needf'd to investi gate th e direct effects of VE GF-A on LEC gene ex pression. with a pmiicular focus on adhe:;ion molec ules and chemokines, whi ch mi ght fa c ilitate canee r cell and ly mphatic vessel int eractions.
PERSPECTIVES
Ln many human ca nce rs, th e lymphatic vasculature represe nts th e most important pathway for tumor cell dis.·emination. and Tobler and Detmar Tumor lymph angiogcn csis a nd m e tas tasis 69a by the sec tumor cell metastasis to LN is a n early event in their metas tati c spread. Most frequen tly. tumor thickness is used as a prognostic parame ter to eva luate the ris k for fut ure metastasis of primar, tumors, but additional marke rs for metastatic spread are urgently needed. Our recent find ings in human ma lignant melanomas _ tha t increased lymphatic vessel density was the single -most signi ficant, independent prognosti c indi cator to predi ct whether the tumors had already me tastasized to the sentinel LN [22] , indieate that beyond mouse models of eancer. the quantitation of tumor lymphangiogenesis mi ght help pati e nts and their physicians to better evaluate the disease prognu~i s and therape ut ic options . Based on our identification of VECF-A as a potent tu mor lyrnph angiogenesis factor. it will be of great interest to see whethe r treatme nt wi th bevacizumab, a neutralizing monoclo nal anti-V E GF -A antibody approved fo r treat ing pati ents with colon cancer, mi ght also inhibit fu rther me tastas ti c spread. Howe ver, th e recent identification of novel lympltangiogenesis factors (Fig. 3) , ineluding hepatocy te growth factor [ 4 7] and angiopoietin-1 [ 48] , indieates that efficie nt. antilymphangiogeni c therapies mi ght need to target addit ionallymphangiogenic moleeules (o r their receptors), whieh are not members of the VEGF fami ly of growth factors .
Although impress ive, new knowl ed ge about the role of lymphatic: vessels in cancer progression has been acquired over the last fe w years, there still remain a number of open question::;: What are the molecular m echanisms that control th e interaction of cancer cells with lymphati c endothelium? Are th ere organ-specific di ffe rences between tumor lymphatics? Are there molecules tha t are specifically expressed by tumorae tivated lymphatic endothelial cells and that mi ght promote lymphatic metastasis? Can we iden tify additional molecules not rela ted to the VE C F/VEGFR s ys tem, which mediate lym-694· Joul'llal of Leukoeyte Biology Volume 80, Oc tober 2 006 vessch withi11 I. r phati c vessel development a nd fun ction, and if so, could these serve as targets for the development of novel , an tica ncer trea tment strategies? Finally, is there a " lymphangioge ne tic" di spositi on tha t predisposes some of us to enhance d lymphatic vessel growth upon stimu la tion and thus to an enhanced risk ~ n tbe fonl1ation
Migration Proliferation Fig. 3 . ~1ol ecu lar control of lympha ngiogenes is. Schematic represe ntation of the major cunently identifi ed lympha ngiogenesis factors a nd their receptors u11 lymp hati c e ndothelium. Angl. An gi opoi~tin -l; HCF. hepatocyt e growth fuctur; HCFH. HCF recep tor; Nrp2. neuropili n-2 .
for eancer metastasis? As a result of the tremendous recent scientific interest in lymphatic research and to th e developrnent of a number of novel research tool , we might soon be Hbl e to provide an answe r to some of these questions.
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